Hims & Hers Health Asserts Demand For Its Compounded …
WEB2 hours ago · Despite semaglutide being the active ingredient in Hims & Hers Health Inc’s (NYSE: HIMS) compounded GLP-1 product, a Truist analyst notes that the recent FDA commentary has reignited investor...
Shares of Hims & Hers Health surge 27% after startup says it will …
WEBMay 20, 2024 · Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections. The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has...
Hims & Hers Health stock tanks after FDA says competitor Eli …
WEB23 hours ago · Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no...
Hims & Hers Health, Inc. (HIMS) Latest Stock News & Headlines …
WEBGet the latest Hims & Hers Health, Inc. (HIMS) stock news and headlines to help you in your trading and investing decisions.
Hims & Hers Is Now Selling Semaglutide: Here's What You …
WEBMay 22, 2024 · Telehealth prescription company Hims & Hers has a new semaglutide initiative. The program will offer compounded semaglutide to customers starting from $199 a month. The company also plans to sell branded Wegovy and Ozempic when it is available.
Hims Inc. - Hims & Hers Health, Inc. Reports Second Quarter …
WEBAug 5, 2024 · SAN FRANCISCO-- (BUSINESS WIRE)-- Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2024 in a shareholder letter that is posted at investors.hims.com.
Hims Inc. - Hims & Hers Expands Into Cardiovascular Health with …
WEBJul 31, 2023 · Hims Hers Health, Inc. (“Hims Hers”, NYSE: HIMS), the leading health and wellness platform, today announced a new approach to enable providers to personalize sexual health treatment for men that also supports cardiovascular health.
Hims Inc. - Hims & Hers Health, Inc. Reports Third Quarter 2023 ...
WEBNov 6, 2023 · Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook. November 6, 2023. Revenue of $226.7 million, up 57% year-over-year in Q3 2023. Net loss of $7.6 million; Adjusted EBITDA profitability of $12.3 million in Q3 2023. Subscribers grew to 1.4 million, up 56% year-over-year in Q3 2023.
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly
WEB1 day ago · Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly’s (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on...
Hims & Hers Expands into Cardiovascular Health with New Dual …
WEBJul 31, 2023 · Today, Hims & Hers announced a new approach to enable providers to personalize sexual health treatment for men that also supports cardiovascular health. Through Heart Health by Hims, providers will be able to personalize treatments to combine active ingredients found in clinically proven...